Establishing Goals of Treatment in Relapsed/Refractory Mantle Cell Lymphoma – [Video Podcast] Ep 51

Staying abreast of recent clinical practice guidelines for the management of relapsed/refractory mantle cell lymphoma can be challenging for providers who may seldom encounter it in community practice. In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-based management of treatment-related adverse events can serve this patient population.

“Fortunately, treatments such as BTK inhibitors are generally very well tolerated by patients, and there are very few patients who can't take a BTK inhibitor. But as you go up the scale of increasing intensity, such as CAR T-cell, or even allogeneic stem cell transplantation, those are therapies not suitable for patients with more extensive comorbidities.” – Dr. Jeff Sharman, MD

“A collaborative relationship between a community practice and an academic center can be of considerable benefit to a patient, so that as treatment decisions are made, both the physician and patient can feel like they're offering the patient the very best therapy.” – Dr. Jeff Sharman, MD

Nirav Shah, MD, MSHP 

Medical Director of Hematology Research, US Oncology

Director of Research

Willamette Valley Cancer Institute

Eugene, Oregon 

This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society.

Resources

• Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC 
• Update on New Therapies
• BTK Inhibitors in MCL
• R/R MCL Case Studies
• BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology 
• Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive 
• HCP Fact Sheet: Facts About CAR T-cell Therapy
• The CAR T-cell Therapy Process
• Patient-Caregiver CAR T-cell Therapy Facts
• Learn About CAR T-cell Therapy  
• Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society